xIPOmeter
IntraBio
IntraBio is a leading biopharmaceutical company that works on new treatments for rare and brain-related diseases. The company is built on the expertise of its founders from the University of Oxford and the University of Munich, focusing on diseases that currently have few or no treatments. IntraBio's research is advanced and aims at improving treatments for various neurological and aging-related conditions. Their work involves cutting-edge science in areas like genetics and brain health, with the goal of developing effective medications for these challenging diseases.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to IntraBio26
IntraBioIntraBio's Pivotal Phase III Trial in CACNA1A-Related Disorders Is ...
IntraBio Inc., a global biopharmaceutical company developing and commercializing therapies for rare and common neurological diseases, today announced that its ...
https://www.morningstar.com/news/business-wire/20260819166437/intrabios-pivotal-phase-iii-trial-in-cacna1a-related-disorders-is-enrolling-and-is-expected-to-be-over-enrolled-and-complete-recruitment-in-octoberIntraBioIntraBio's Pivotal Phase III Trial in CACNA1A-Related Disorders Is ...
IntraBio's Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October ...
https://finance.yahoo.com/healthcare/articles/intrabio-pivotal-phase-iii-trial-130000830.htmlIntraBioIntraBio Announces Publication of New Research Showing a Direct ...
IntraBio Announces Publication of New Research Showing a Direct, Bidirectional Effect on Lysosomal Function with Levacetylleucine ...
https://finance.yahoo.com/healthcare/articles/intrabio-announces-publication-research-showing-123000896.htmlIntraBioIntraBio Announces Publication of Pivotal Phase III Data with ...
IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) ...
https://www.morningstar.com/news/business-wire/20260618205413/intrabio-announces-publication-of-pivotal-phase-iii-data-with-levacetylleucine-for-ataxia-telangiectasia-in-the-lancet-neurologyIntraBioIntraBio Announces Submission of Variation Application to the ...
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia ...
https://finance.yahoo.com/sectors/healthcare/articles/intrabio-announces-submission-variation-application-150900330.html
Show more (21)